GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
The phase I/II TH HSV REC-003 study evaluated the clinical efficacy of the early-stage HSV vaccine candidate GSK3943104. The company completed the primary objective data analysis from the phase II part of the phase I/II TH HSV REC-003 study, which demonstrated that GSK3943104 failed to meet the study's primary efficacy endpoint. Following this, the company decided not to progress with phase III development of GSK3943104. Shares of GSK have rallied 18.1% so far this year against the industry's decline of 1%. Image Source: Zacks Investment Research Positive Data From GSK's mRNA-based Flu Vaccine Program In a separate press release, GSK announced positive headline data from a phase II study that evaluated certain mRNA-based seasonal influenza vaccine candidates. The study investigated various mRNA formulations of the seasonal influenza vaccine candidates, which can improve immune responses against influenza A and B strains in older and younger adults versus the current sta
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble? [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech to Present at 2024 Cantor Global Healthcare ConferenceGlobeNewswire
- Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Stifel Nicolaus from $204.00 to $220.00. They now have a "buy" rating on the stock.MarketBeat
- Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Krystal Biotech, Inc. (NASDAQ: KRYS) was upgraded by analysts at William Blair to a "strong-buy" rating.MarketBeat
KRYS
Earnings
- 8/5/24 - Beat
KRYS
Sec Filings
- 9/13/24 - Form 4
- 9/13/24 - Form 4
- 9/13/24 - Form 4
- KRYS's page on the SEC website